These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33218684)

  • 1. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
    Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
    Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
    Liao Y; Guo Y; Li S; Wang L; Tang Y; Li T; Chen W; Zhong G; Song G
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1188-1193. PubMed ID: 29545101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
    Song G; Zhao D; Hu D; Li Y; Jin H; Cui Z
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4610-4. PubMed ID: 26320621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
    Zhang X; Dong G; Li H; Chen W; Li J; Feng C; Gu Z; Zhu F; Zhang R; Li M; Tang W; Liu H; Xu Y
    J Med Chem; 2019 Jun; 62(11):5579-5593. PubMed ID: 31099559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
    Song G; Zhu X; Li J; Hu D; Zhao D; Liao Y; Lin J; Zhang LH; Cui ZN
    Bioorg Med Chem; 2017 Oct; 25(20):5709-5717. PubMed ID: 28888661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors.
    Guariento S; Karawajczyk A; Bull JA; Marchini G; Bielska M; Iwanowa X; Bruno O; Fossa P; Giordanetto F
    Bioorg Med Chem Lett; 2017 Jan; 27(1):24-29. PubMed ID: 27890378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.
    Barberot C; Moniot A; Allart-Simon I; Malleret L; Yegorova T; Laronze-Cochard M; Bentaher A; Médebielle M; Bouillon JP; Hénon E; Sapi J; Velard F; Gérard S
    Eur J Med Chem; 2018 Feb; 146():139-146. PubMed ID: 29407945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
    Purushothaman B; Arumugam P; Kulsi G; Song JM
    Eur J Med Chem; 2018 Feb; 145():673-690. PubMed ID: 29353721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.
    Liao Y; Jia X; Tang Y; Li S; Zang Y; Wang L; Cui ZN; Song G
    Bioorg Med Chem Lett; 2019 Nov; 29(22):126720. PubMed ID: 31610942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and bioactivity of pyrazole and triazole derivatives as potential PDE4 inhibitors.
    Li YS; Tian H; Zhao DS; Hu DK; Liu XY; Jin HW; Song GP; Cui ZN
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3632-5. PubMed ID: 27289320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling.
    Li H; Li J; Zhang X; Feng C; Fan C; Yang X; Zhang R; Zhu F; Zhou Y; Xu Y; Liu H; Tang W
    Biochem Pharmacol; 2020 Jul; 177():113958. PubMed ID: 32251674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting next-generation PDE4 inhibitors in search of potential management of rheumatoid arthritis and psoriasis.
    Bhuktar H; Thirupataiah B; Mounika G; Samarpita S; Rithvik A; Sasi Priya SVS; Naskar R; Medishetti R; Jagadish PC; Parsa KVL; Rasool M; Chakraborty S; Pal M
    Bioorg Chem; 2024 Oct; 151():107689. PubMed ID: 39111119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
    Chłoń-Rzepa G; Jankowska A; Ślusarczyk M; Świerczek A; Pociecha K; Wyska E; Bucki A; Gawalska A; Kołaczkowski M; Pawłowski M
    Eur J Med Chem; 2018 Feb; 146():381-394. PubMed ID: 29407965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effects.
    Zhou F; Huang Y; Liu L; Song Z; Hou KQ; Yang Y; Luo HB; Huang YY; Xiong XF
    Biochem Pharmacol; 2022 Aug; 202():115123. PubMed ID: 35688178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.
    Song Z; Huang YY; Hou KQ; Liu L; Zhou F; Huang Y; Wan G; Luo HB; Xiong XF
    J Med Chem; 2022 Mar; 65(5):4238-4254. PubMed ID: 35188767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
    Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
    J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
    Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
    Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
    Chu Z; Xu Q; Zhu Q; Ma X; Mo J; Lin G; Zhao Y; Gu Y; Bian L; Shao L; Guo J; Ye W; Li J; He G; Xu Y
    Eur J Med Chem; 2021 Mar; 213():113171. PubMed ID: 33482600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
    Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
    Bioorg Med Chem; 2013 Nov; 21(22):7025-37. PubMed ID: 24094436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel N-indolylmethyl substituted olanzapine derivatives: their design, synthesis and evaluation as PDE4B inhibitors.
    Gorja DR; Mukherjee S; Meda CL; Deora GS; Kumar KL; Jain A; Chaudhari GH; Chennubhotla KS; Banote RK; Kulkarni P; Parsa KV; Mukkanti K; Pal M
    Org Biomol Chem; 2013 Apr; 11(13):2075-9. PubMed ID: 23436140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.